Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a note issued to investors on Saturday, Zacks.com reports. The firm currently has a $17.00 price target on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 9.18% from the company’s previous close.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other equities analysts have also recently commented on KURA. ValuEngine cut Kura Oncology from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Kura Oncology in a research note on Friday, August 2nd. JMP Securities reissued a “market outperform” rating and set a $22.00 target price on shares of Kura Oncology in a research note on Thursday, September 5th. Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Wednesday, November 6th. Finally, Wedbush reissued a “positive” rating on shares of Kura Oncology in a report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $26.11.
Shares of KURA traded up $0.04 during trading hours on Friday, reaching $15.57. 19,007 shares of the company’s stock traded hands, compared to its average volume of 264,753. The stock has a market cap of $672.35 million, a PE ratio of -9.05 and a beta of 2.57. The company has a current ratio of 23.50, a quick ratio of 23.50 and a debt-to-equity ratio of 0.03. The firm’s 50 day simple moving average is $14.92 and its 200-day simple moving average is $16.88. Kura Oncology has a 12 month low of $11.01 and a 12 month high of $21.42.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.03. As a group, analysts expect that Kura Oncology will post -1.61 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new stake in shares of Kura Oncology during the second quarter worth about $25,000. Meeder Asset Management Inc. grew its position in shares of Kura Oncology by 164.9% in the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after purchasing an additional 1,204 shares in the last quarter. Bank of Montreal Can lifted its holdings in Kura Oncology by 82,066.7% in the second quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after acquiring an additional 2,462 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Kura Oncology by 599.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after acquiring an additional 2,420 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Kura Oncology during the second quarter worth $59,000. Institutional investors and hedge funds own 84.97% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.